Tenax Therapeutics shares are trading higher after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a price target of $16.
Portfolio Pulse from Benzinga Newsdesk
Tenax Therapeutics shares rose after Leerink Partners initiated coverage with an Outperform rating and set a price target of $16.
October 24, 2024 | 7:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tenax Therapeutics shares increased following Leerink Partners' initiation of coverage with an Outperform rating and a $16 price target.
The initiation of coverage by Leerink Partners with an Outperform rating and a $16 price target is a positive signal for investors, likely leading to increased buying interest and a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100